



29 August 2024

cyclopharm
cyclopharm
technegas
ultralute

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

1H 2024 RESULTS AND USA TECHNEGAS COMMERCIALISATION UPDATE

Cyclopharm (ASX:CYC), the health technology company that is world leader in functional lung ventilation imaging, will be providing a 1H 2024 results call and an update on the commercialisation progress for Technegas in the USA for shareholders and investors on Tuesday, 03 September 2024.

The webinar will commence at 11.00 (AEST) on Tuesday, 03 September 2024. All shareholders and investors are welcome to attend, with registration via the address below:

https://us02web.zoom.us/webinar/register/WN_dTizi89_TOG80twGvS2qlA#/registration

Once registered, participants will be provided with full details of the link to the webinar.

ENDS

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.